Fas and Fas ligand expression in the salivary glands of patients with primary Sjögren's syndrome. 1997

L Kong, and N Ogawa, and T Nakabayashi, and G T Liu, and E D'Souza, and H S McGuff, and D Guerrero, and N Talal, and H Dang
University of Texas Health Science Center, San Antonio 78284-7874, USA.

OBJECTIVE To assess the role of Fas-mediated apoptosis in the salivary glands of patients with primary Sjögren's syndrome (SS). METHODS Expression of Fas, Fas ligand (FasL), and bcl-2 in salivary gland biopsy material was detected in situ by immunohistochemical staining and reverse transcriptase-polymerase chain reaction. DNA fragmentation in apoptotic cells was assessed by the enzymatic incorporation of labeled nucleotides (digoxigenin-dUTP). RESULTS The acinar epithelial cells in SS were Fas+ and FasL+, and these cells died by apoptosis. The majority of infiltrating lymphocytes in SS were Fas+ and bcl-2+, while few lymphocytes expressed FasL. In situ detection of apoptosis showed minimal cell death of lymphocytes, particularly in dense periductal foci. Lymphocytic cell death was significantly lower (P < 0.0001) in these foci compared with that in the interstitium. CONCLUSIONS Infiltrating lymphocytes in the focal lesions of the salivary glands of patients with SS are blocked in their ability to commit to apoptosis, even though they may express Fas. The presence of bcl-2 in these cells may explain their inability to undergo apoptosis. The acinar epithelial cells, in contrast, may undergo Fas-mediated apoptosis. These results suggest that the Fas death pathway may be an important mechanism leading to the glandular destruction found in SS.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008297 Male Males
D008562 Membrane Glycoproteins Glycoproteins found on the membrane or surface of cells. Cell Surface Glycoproteins,Surface Glycoproteins,Cell Surface Glycoprotein,Membrane Glycoprotein,Surface Glycoprotein,Glycoprotein, Cell Surface,Glycoprotein, Membrane,Glycoprotein, Surface,Glycoproteins, Cell Surface,Glycoproteins, Membrane,Glycoproteins, Surface,Surface Glycoprotein, Cell,Surface Glycoproteins, Cell
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012469 Salivary Glands Glands that secrete SALIVA in the MOUTH. There are three pairs of salivary glands (PAROTID GLAND; SUBLINGUAL GLAND; SUBMANDIBULAR GLAND). Gland, Salivary,Glands, Salivary,Salivary Gland
D012859 Sjogren's Syndrome Chronic inflammatory and autoimmune disease in which the salivary and lacrimal glands undergo progressive destruction by lymphocytes and plasma cells resulting in decreased production of saliva and tears. The primary form, often called sicca syndrome, involves both KERATOCONJUNCTIVITIS SICCA and XEROSTOMIA. The secondary form includes, in addition, the presence of a connective tissue disease, usually rheumatoid arthritis. Sicca Syndrome,Sjogren Syndrome,Sjogrens Syndrome,Syndrome, Sicca,Syndrome, Sjogren's
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D053222 Fas Ligand Protein A transmembrane protein belonging to the tumor necrosis factor superfamily that was originally discovered on cells of the lymphoid-myeloid lineage, including activated T-LYMPHOCYTES and NATURAL KILLER CELLS. It plays an important role in immune homeostasis and cell-mediated toxicity by binding to the FAS RECEPTOR and triggering APOPTOSIS. Antigens, CD178,CD178 Antigens,Tumor Necrosis Factor Ligand Superfamily Member 6,CD178 Antigen,CD95 Antigen Ligand,CD95 Ligand,CD95L,Fas Ligand,Fas Ligand (FasL),FasL Protein,TNF Superfamily, Member 6,Antigen, CD178

Related Publications

L Kong, and N Ogawa, and T Nakabayashi, and G T Liu, and E D'Souza, and H S McGuff, and D Guerrero, and N Talal, and H Dang
January 1992, Autoimmunity,
L Kong, and N Ogawa, and T Nakabayashi, and G T Liu, and E D'Souza, and H S McGuff, and D Guerrero, and N Talal, and H Dang
October 2000, The Journal of rheumatology,
L Kong, and N Ogawa, and T Nakabayashi, and G T Liu, and E D'Souza, and H S McGuff, and D Guerrero, and N Talal, and H Dang
July 2014, Rheumatology (Oxford, England),
L Kong, and N Ogawa, and T Nakabayashi, and G T Liu, and E D'Souza, and H S McGuff, and D Guerrero, and N Talal, and H Dang
July 2002, Clinical and experimental immunology,
L Kong, and N Ogawa, and T Nakabayashi, and G T Liu, and E D'Souza, and H S McGuff, and D Guerrero, and N Talal, and H Dang
January 1998, Clinical and experimental rheumatology,
L Kong, and N Ogawa, and T Nakabayashi, and G T Liu, and E D'Souza, and H S McGuff, and D Guerrero, and N Talal, and H Dang
January 1986, Scandinavian journal of rheumatology. Supplement,
L Kong, and N Ogawa, and T Nakabayashi, and G T Liu, and E D'Souza, and H S McGuff, and D Guerrero, and N Talal, and H Dang
March 2002, Human cell,
L Kong, and N Ogawa, and T Nakabayashi, and G T Liu, and E D'Souza, and H S McGuff, and D Guerrero, and N Talal, and H Dang
August 1999, Journal of autoimmunity,
L Kong, and N Ogawa, and T Nakabayashi, and G T Liu, and E D'Souza, and H S McGuff, and D Guerrero, and N Talal, and H Dang
November 2007, Autoimmunity,
L Kong, and N Ogawa, and T Nakabayashi, and G T Liu, and E D'Souza, and H S McGuff, and D Guerrero, and N Talal, and H Dang
December 2000, Arthritis and rheumatism,
Copied contents to your clipboard!